Overview

uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness

Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Prospective study to evaluate the value of uPAR-targeted PET/MR scan using the tracer 68Ga-NOTA-AE105 in patients with newly diagnosed prostate cancer
Phase:
Phase 2
Details
Lead Sponsor:
Rigshospitalet, Denmark